$TKNO
Alpha Teknova, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096441 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q4
Revenue $9.576M $9.614M $7.867M
YoY Change 17.22% -16.6% -0.3%
Cost Of Revenue $9.486M $6.810M $6.532M
YoY Change 41.65% 5.4% 12.99%
Gross Profit $90.00K $2.804M $1.335M
YoY Change -93.89% -44.65% -36.73%
Gross Profit Margin 0.94% 29.17% 16.97%
Selling, General & Admin $6.608M $6.939M $8.425M
YoY Change -22.71% -14.51% -15.76%
% of Gross Profit 7342.22% 247.47% 631.09%
Research & Development $627.0K $678.0K $1.311M
YoY Change -55.12% -53.69% -29.89%
% of Gross Profit 696.67% 24.18% 98.2%
Depreciation & Amortization $1.400M $1.300M $1.611M
YoY Change 7.69% 30.0% 80.4%
% of Gross Profit 1555.56% 46.36% 120.67%
Operating Expenses $7.522M $7.904M $10.02M
YoY Change -26.5% -34.48% -17.55%
Operating Profit -$7.432M -$5.100M -$8.689M
YoY Change -15.18% -27.11% -13.53%
Interest Expense -$141.0K -$272.0K -$440.0K
YoY Change -82.15% -11.69% -443.75%
% of Operating Profit
Other Income/Expense, Net -$141.0K -$272.0K $338.0K
YoY Change -89.8% 91.55% 1678.95%
Pretax Income -$7.573M -$5.372M -$10.96M
YoY Change -25.35% -24.75% -22.21%
Income Tax -$8.000K -$8.000K -$304.0K
% Of Pretax Income
Net Earnings -$7.565M -$5.364M -$10.66M
YoY Change -25.49% -25.02% -19.84%
Net Earnings / Revenue -79.0% -55.79% -135.45%
Basic Earnings Per Share -$0.15 -$0.13
Diluted Earnings Per Share -$0.15 -$0.13 -$0.26
COMMON SHARES
Basic Shares Outstanding 53.30M 40.82M 40.73M
Diluted Shares Outstanding 51.82M 40.85M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.69M $18.60M $28.59M
YoY Change -1.27% -21.57% -32.3%
Cash & Equivalents $6.145M $18.60M $28.59M
Short-Term Investments $25.55M
Other Short-Term Assets $1.960M $1.104M $1.524M
YoY Change -18.33% -36.59% -35.8%
Inventory $7.674M $10.99M $11.59M
Prepaid Expenses
Receivables $4.605M $4.597M $3.948M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $45.93M $35.28M $45.66M
YoY Change -10.08% -18.16% -25.32%
LONG-TERM ASSETS
Property, Plant & Equipment $46.72M $47.78M $66.84M
YoY Change -9.43% -9.62% -6.28%
Goodwill
YoY Change
Intangibles $13.38M $13.67M $14.24M
YoY Change -19.87% -19.54% -18.89%
Long-Term Investments
YoY Change
Other Assets $1.518M $1.646M $1.852M
YoY Change -22.23% -18.92% -17.76%
Total Long-Term Assets $78.17M $80.07M $82.93M
YoY Change -10.47% -10.47% -8.99%
TOTAL ASSETS
Total Short-Term Assets $45.93M $35.28M $45.66M
Total Long-Term Assets $78.17M $80.07M $82.93M
Total Assets $124.1M $115.4M $128.6M
YoY Change -10.32% -12.97% -15.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $975.0K $1.023M $1.493M
YoY Change -31.43% -5.37% -39.04%
Accrued Expenses $4.373M $3.498M $7.382M
YoY Change -15.04% -4.37% -12.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.528M $1.011M $0.00
YoY Change -95.44%
Total Short-Term Liabilities $9.719M $7.413M $8.875M
YoY Change 16.55% -74.13% -18.39%
LONG-TERM LIABILITIES
Long-Term Debt $10.86M $12.27M $13.25M
YoY Change -17.55% -39.7%
Other Long-Term Liabilities $15.39M $15.87M $15.51M
YoY Change -3.83% -3.66% -15.28%
Total Long-Term Liabilities $10.86M $12.27M $28.76M
YoY Change -17.55% -28.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.719M $7.413M $8.875M
Total Long-Term Liabilities $10.86M $12.27M $28.76M
Total Liabilities $36.83M $36.43M $38.55M
YoY Change -4.91% -21.4% -26.4%
SHAREHOLDERS EQUITY
Retained Earnings -$112.8M -$105.2M -$91.80M
YoY Change 39.1% 48.24% 66.91%
Common Stock $1.000K $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.27M $78.93M $90.04M
YoY Change
Total Liabilities & Shareholders Equity $124.1M $115.4M $128.6M
YoY Change -10.32% -12.97% -15.55%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q4
OPERATING ACTIVITIES
Net Income -$7.565M -$5.364M -$10.66M
YoY Change -25.49% -25.02% -19.84%
Depreciation, Depletion And Amortization $1.400M $1.300M $1.611M
YoY Change 7.69% 30.0% 80.4%
Cash From Operating Activities -$2.059M -$2.838M -$2.782M
YoY Change -52.99% -26.4% -65.35%
INVESTING ACTIVITIES
Capital Expenditures $331.0K $115.0K $312.0K
YoY Change -65.88% -95.08% -93.4%
Acquisitions
YoY Change
Other Investing Activities -$25.43M $0.00 $197.0K
YoY Change
Cash From Investing Activities -$25.76M -$115.0K -$115.0K
YoY Change 2555.57% -95.08% -97.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.37M -47.00K -621.0K
YoY Change 12.74% -73.89% -112.08%
NET CHANGE
Cash From Operating Activities -2.059M -2.838M -2.782M
Cash From Investing Activities -25.76M -115.0K -115.0K
Cash From Financing Activities 15.37M -47.00K -621.0K
Net Change In Cash -12.45M -3.000M -3.518M
YoY Change -250.37% -52.93% -53.83%
FREE CASH FLOW
Cash From Operating Activities -$2.059M -$2.838M -$2.782M
Capital Expenditures $331.0K $115.0K $312.0K
Free Cash Flow -$2.390M -$2.953M -$3.094M
YoY Change -55.33% -52.32% -75.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001850902
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40538
dei Entity Registrant Name
EntityRegistrantName
ALPHA TEKNOVA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3368109
dei Entity Address Address Line1
EntityAddressAddressLine1
2451 Bert Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Hollister
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95023
dei City Area Code
CityAreaCode
831
dei Local Phone Number
LocalPhoneNumber
637-1100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
TKNO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53302993
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9614000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11527000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18904000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20648000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6810000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6461000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13891000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13159000
CY2024Q2 us-gaap Gross Profit
GrossProfit
2804000
CY2023Q2 us-gaap Gross Profit
GrossProfit
5066000
us-gaap Gross Profit
GrossProfit
5013000
us-gaap Gross Profit
GrossProfit
7489000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
678000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1464000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1538000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2859000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1456000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2174000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3123000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4517000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5483000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5943000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12864000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13288000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
287000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
287000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
574000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
573000
CY2024Q2 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
0
CY2023Q2 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
2195000
tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
0
tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
2195000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
7904000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
12063000
us-gaap Operating Expenses
OperatingExpenses
18099000
us-gaap Operating Expenses
OperatingExpenses
23432000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5100000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6997000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13086000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15943000
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-272000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-308000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-417000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-215000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
166000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
184000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-272000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-142000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-417000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5372000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7139000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13503000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15974000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-42000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5364000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7154000
us-gaap Net Income Loss
NetIncomeLoss
-13461000
us-gaap Net Income Loss
NetIncomeLoss
-15971000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40853882
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40853882
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28272306
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28272306
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40829383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40829383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28227132
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28227132
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18596000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28484000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
74000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
20000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4597000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3948000
CY2024Q2 us-gaap Inventory Net
InventoryNet
10987000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11594000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1104000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1634000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
35284000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
45660000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47777000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50364000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16981000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16472000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13665000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14239000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1646000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1852000
CY2024Q2 us-gaap Assets
Assets
115353000
CY2023Q4 us-gaap Assets
Assets
128587000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1023000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1493000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3498000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1881000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1803000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1011000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7413000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8875000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
875000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
919000
CY2024Q2 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
54000
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
102000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12271000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13251000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15812000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15404000
CY2024Q2 us-gaap Liabilities
Liabilities
36425000
CY2023Q4 us-gaap Liabilities
Liabilities
38551000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40915331
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40915331
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40793848
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40793848
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
184175000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
181822000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105247000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91786000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
78928000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
90036000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115353000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128587000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
83378000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
833000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
81000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5364000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
78928000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
92087000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1070000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
138000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7154000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
86208000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
90036000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
132000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2140000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
81000
us-gaap Net Income Loss
NetIncomeLoss
-13461000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
78928000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
99885000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2080000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
138000
us-gaap Net Income Loss
NetIncomeLoss
-15971000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
86208000
us-gaap Net Income Loss
NetIncomeLoss
-13461000
us-gaap Net Income Loss
NetIncomeLoss
-15971000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
56000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8000
us-gaap Inventory Write Down
InventoryWriteDown
896000
us-gaap Inventory Write Down
InventoryWriteDown
33000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3262000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2427000
us-gaap Share Based Compensation
ShareBasedCompensation
2140000
us-gaap Share Based Compensation
ShareBasedCompensation
2080000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-44000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-4000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
188000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
210000
tkno Non Cash Lease Expense
NonCashLeaseExpense
94000
tkno Non Cash Lease Expense
NonCashLeaseExpense
31000
tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
0
tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
2195000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-49000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
705000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
319000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
1050000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
289000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-196000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-413000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1042000
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-206000
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-222000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-389000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1362000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1764000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1234000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-48000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-44000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9396000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11540000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
125000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
227000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6650000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-102000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6650000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-37000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
tkno Repayment Of Financed Insurance Premiums
RepaymentOfFinancedInsurancePremiums
409000
tkno Repayment Of Financed Insurance Premiums
RepaymentOfFinancedInsurancePremiums
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
25000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
24000
tkno Payment Of At The Market Facility Costs
PaymentOfAtTheMarketFacilityCosts
0
tkno Payment Of At The Market Facility Costs
PaymentOfAtTheMarketFacilityCosts
395000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
81000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
138000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-390000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-205000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9888000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18395000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28484000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42236000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18596000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23841000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Interest Paid Net
InterestPaidNet
770000
us-gaap Interest Paid Net
InterestPaidNet
630000
tkno Capitalized Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities
CapitalizedPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
99000
tkno Capitalized Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities
CapitalizedPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
920000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
132000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0
tkno Recognition Of Operating Right Of Use Lease Asset
RecognitionOfOperatingRightOfUseLeaseAsset
1293000
tkno Recognition Of Operating Right Of Use Lease Asset
RecognitionOfOperatingRightOfUseLeaseAsset
-1137000
tkno Recognition Of Operating Lease Liabilities
RecognitionOfOperatingLeaseLiabilities
1306000
tkno Recognition Of Operating Lease Liabilities
RecognitionOfOperatingLeaseLiabilities
-1193000
us-gaap Nature Of Operations
NatureOfOperations
<p id="i_notes" style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Nature of th</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Business</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Teknova produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our product offerings include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Teknova manufactures its products at its Hollister, California, headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister to its customers and distributors.</span></p>
tkno Warrants Policy Policytextblock
WarrantsPolicyPolicytextblock
<p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 480) and ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASC 815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9614000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11527000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18904000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20648000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9614000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11527000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18904000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20648000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7969000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8573000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
140000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
47000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2878000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2974000
CY2024Q2 us-gaap Inventory Net
InventoryNet
10987000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11594000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55693000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55888000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10104000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7528000
CY2024Q2 tkno Property Plant And Equipment After Depreciation
PropertyPlantAndEquipmentAfterDepreciation
45589000
CY2023Q4 tkno Property Plant And Equipment After Depreciation
PropertyPlantAndEquipmentAfterDepreciation
48360000
CY2024Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2188000
CY2023Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2004000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47777000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50364000
CY2024Q2 us-gaap Depreciation
Depreciation
1300000
us-gaap Depreciation
Depreciation
2700000
CY2023Q2 us-gaap Depreciation
Depreciation
1000000
us-gaap Depreciation
Depreciation
1900000
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0
CY2024Q2 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0
CY2023Q2 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
300000
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
900000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
745000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
641000
us-gaap Operating Lease Cost
OperatingLeaseCost
1491000
us-gaap Operating Lease Cost
OperatingLeaseCost
1401000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
109000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
54000
us-gaap Variable Lease Cost
VariableLeaseCost
217000
us-gaap Variable Lease Cost
VariableLeaseCost
110000
CY2024Q2 us-gaap Lease Cost
LeaseCost
854000
CY2023Q2 us-gaap Lease Cost
LeaseCost
695000
us-gaap Lease Cost
LeaseCost
1708000
us-gaap Lease Cost
LeaseCost
1511000
CY2024Q2 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
700000
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
1400000
CY2023Q2 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
700000
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
1500000
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.049
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1404000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2569000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2627000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2631000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2480000
CY2024Q2 tkno Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
10296000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
22007000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4314000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
17693000
CY2024Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
19930000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6265000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13665000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
19930000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5691000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14239000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P2Y6M
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
574000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1148000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1148000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
45000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2915000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2080000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3826000
CY2024Q2 tkno Accrued Liabilities Property Plant And Equipment Current
AccruedLiabilitiesPropertyPlantAndEquipmentCurrent
92000
CY2023Q4 tkno Accrued Liabilities Property Plant And Equipment Current
AccruedLiabilitiesPropertyPlantAndEquipmentCurrent
0
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
24000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
16000
CY2024Q2 tkno Insurance Premiums And Accrued Interest
InsurancePremiumsAndAccruedInterest
0
CY2023Q4 tkno Insurance Premiums And Accrued Interest
InsurancePremiumsAndAccruedInterest
409000
CY2024Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
373000
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
300000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
929000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1028000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3498000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2024Q1 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
5000000
CY2024Q1 us-gaap Line Of Credit Facility Description
LineOfCreditFacilityDescription
If any advance under the Term Loan is prepaid at any time, a prepayment fee is based on the amount being prepaid and an applicable percentage amount, such as 4%, 3%, or 1%, based on the date the prepayment is made
CY2024Q1 us-gaap Debt Instrument Covenant Description
DebtInstrumentCovenantDescription
No. 5 also removed those requirements for the periods ending January 31, 2025 through December 31, 2025, instead requiring that for each applicable twelve-month period ending after December 31, 2024, the Company’s minimum net revenue requirement will be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in the Amended Credit Agreement, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $34.0 million
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
100000
CY2024Q1 tkno Term Loan Exit Fee Percent
TermLoanExitFeePercent
0.09
CY2024Q2 tkno Term Loan
TermLoan
12135000
CY2023Q4 tkno Term Loan
TermLoan
12135000
CY2024Q2 tkno Debt Instrument Cumulative Accretion Of Exit Fee
DebtInstrumentCumulativeAccretionOfExitFee
1401000
CY2023Q4 tkno Debt Instrument Cumulative Accretion Of Exit Fee
DebtInstrumentCumulativeAccretionOfExitFee
1261000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
254000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
145000
CY2024Q2 tkno Total Debt Amount
TotalDebtAmount
13282000
CY2023Q4 tkno Total Debt Amount
TotalDebtAmount
13251000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1011000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
12271000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
13251000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3539000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6068000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2528000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12135000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.3535
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.3591
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.3504
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0347
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0433
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0411
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q2 tkno Weighted Average Fair Value Of Common Stock
WeightedAverageFairValueOfCommonStock
1.97
tkno Weighted Average Fair Value Of Common Stock
WeightedAverageFairValueOfCommonStock
2.85
tkno Weighted Average Fair Value Of Common Stock
WeightedAverageFairValueOfCommonStock
5.37
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.28
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
833000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1070000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2140000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2080000
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5364000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7154000
us-gaap Net Income Loss
NetIncomeLoss
-13461000
us-gaap Net Income Loss
NetIncomeLoss
-15971000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40853882
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40853882
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28272306
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28272306
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40829383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40829383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28227132
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28227132
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2023Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
300000
CY2024Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
400000
CY2024Q2 tkno Contingent Liability Of Acrual Increment
ContingentLiabilityOfAcrualIncrement
100000
CY2024Q2 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
400000

Files In Submission

Name View Source Status
0000950170-24-096441-index-headers.html Edgar Link pending
0000950170-24-096441-index.html Edgar Link pending
0000950170-24-096441.txt Edgar Link pending
0000950170-24-096441-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkno-20240630.htm Edgar Link pending
tkno-20240630.xsd Edgar Link pending
tkno-ex31_1.htm Edgar Link pending
tkno-ex31_2.htm Edgar Link pending
tkno-ex32_1.htm Edgar Link pending
tkno-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable